GRM1 and Parkinson disease: For example, longitudinal positron emission tomography (PET) imaging using [11C]ITDM (N-[4-[6-(isopropylamino) pyrimidin-4-yl]-1,3-thiazol-2-yl]-N-methyl-4-[11C]methylbenzamide) and (E)-[11C]ABP688 [3-(6-methylpyridin-2-ylethynyl)-cyclohex-2-enone-(E)-0-[11C] methyloxime] ligands for mGluR1 and mGluR5, respectively, showed dramatic changes in striatal non-displaceable binding potential (BPND) values of both receptors with PD progression [70].